首页> 外文期刊>ACS nano >Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation
【24h】

Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation

机译:膨胀纳米颗粒的放射性标记生物分布:腹膜内给药导致肿瘤特异性积累

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Nanoparticle biodistribution in vivo is an essential component to the success of nanoparticle-based drug delivery systems. Previous studies with fluorescently labeled expansile nanoparticles, or “eNPs”, demonstrated a high specificity of eNPs to tumors that is achieved through a materials-based targeting strategy. However, fluorescent labeling techniques are primarily qualitative in nature and the gold-standard for quantitative evaluation of biodistribution is through radiolabeling. In this manuscript, we synthesize 14C-labeled eNPs to quantitatively evaluate the biodistribution of these particles in a murine model of intraperitoneal mesothelioma via liquid scintillation counting. The results demonstrate a strong specificity of eNPs for tumors that lasts one to 2 weeks postinjection with an overall delivery efficiency to the tumor tissue of 30 of the injected dose which is congruent with prior reports of preclinical efficacy of the technology. Importantly, the route of administration is essential to the eNP’s material-based targeting strategy with intraperitoneal administration leading to tumoral accumulation while, in contrast, intravenous administration leads to rapid clearance via the reticuloendothelial system and low tumoral accumulation. A comparison against nanoparticle delivery systems published over the past decade shows that the 30 tumoral delivery efficiency of the eNP is significantly higher than the 0.7 median delivery efficiency of other systems with sufficient quantitative data to define this metric. These results lay a foundation for targeting intraperitoneal tumors and encourage efforts to explore alternative, nonintravenous routes, of delivery to accelerate the translation of nanoparticle therapies to the clinic.
机译:纳米颗粒在体内的生物分布是基于纳米颗粒的药物递送系统成功的重要组成部分。先前对荧光标记膨胀纳米颗粒(“eNPs”)的研究表明,eNPs对肿瘤具有高度特异性,这是通过基于材料的靶向策略实现的。然而,荧光标记技术本质上是定性的,定量评估生物分布的金标准是通过放射性标记。在这篇手稿中,我们合成了 14C 标记的 eNPs,通过液体闪烁计数定量评估这些颗粒在腹膜内间皮瘤小鼠模型中的生物分布。结果表明,eNPs对肿瘤具有很强的特异性,在注射后持续1至2周,对肿瘤组织的总体递送效率为注射剂量的30%,这与先前关于该技术临床前疗效的报道一致。重要的是,给药途径对于 eNP 基于材料的靶向策略至关重要,腹膜内给药会导致肿瘤积累,而相比之下,静脉内给药会导致通过网状内皮系统快速清除和低肿瘤积累。与过去十年发表的纳米颗粒递送系统的比较表明,eNP 的 30% 肿瘤递送效率明显高于 0.其他系统的交付效率中位数为 7%,具有足够的定量数据来定义该指标。这些结果为靶向腹膜内肿瘤奠定了基础,并鼓励人们努力探索替代的非静脉内给药途径,以加速纳米颗粒疗法向临床的转化。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号